Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9

Rhea-AI Summary

Royalty Pharma, listed on Nasdaq as RPRX, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The presentation can be accessed via the company's Events page and will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leader in biopharmaceutical royalties, funding innovation through collaborations with various biopharmaceutical entities. Its portfolio includes royalties from over 35 commercial products.

NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 11 development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When is Royalty Pharma's presentation at the J.P. Morgan Healthcare Conference?

Royalty Pharma will present at the J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET.

How can I access the webcast of Royalty Pharma's presentation?

The webcast for Royalty Pharma's presentation can be accessed on their Events page.

Will the webcast of Royalty Pharma's presentation be available later?

Yes, the webcast will be archived for a minimum of thirty days.

What is the stock symbol for Royalty Pharma?

Royalty Pharma's stock symbol is RPRX.

What does Royalty Pharma do?

Royalty Pharma is the largest buyer of biopharmaceutical royalties, collaborating with various entities to fund innovation in the industry.